ADC Therapeutics SA
ADCT
$3.43
-$0.05-1.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.43% | 14.85% | 6.35% | 15.73% | 10.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.43% | 14.85% | 6.35% | 15.73% | 10.49% |
| Cost of Revenue | -14.37% | -5.74% | -1.50% | 8.55% | -2.30% |
| Gross Profit | 49.14% | 39.48% | 13.09% | 1.90% | 19.52% |
| SG&A Expenses | -1.52% | -6.61% | -11.74% | -12.49% | -15.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.02% | -6.11% | -5.92% | -0.96% | -8.21% |
| Operating Income | 17.23% | 17.61% | 12.20% | 8.99% | 16.80% |
| Income Before Tax | 9.04% | 10.19% | 1.57% | 1.56% | 20.61% |
| Income Tax Expenses | 405.95% | 511.45% | -97.48% | -97.27% | -99.57% |
| Earnings from Continuing Operations | 8.58% | 9.64% | 21.31% | 20.92% | 34.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.58% | 9.64% | 21.31% | 20.92% | 34.07% |
| EBIT | 17.23% | 17.61% | 12.20% | 8.99% | 16.80% |
| EBITDA | 16.76% | 17.30% | 12.12% | 9.13% | 17.01% |
| EPS Basic | 24.29% | 27.55% | 39.57% | 38.41% | 47.48% |
| Normalized Basic EPS | 33.24% | 35.21% | 29.88% | 29.11% | 37.30% |
| EPS Diluted | 24.29% | 27.55% | 39.57% | 38.41% | 47.48% |
| Normalized Diluted EPS | 33.24% | 35.21% | 29.88% | 29.11% | 37.30% |
| Average Basic Shares Outstanding | 27.73% | 30.69% | 26.67% | 25.78% | 25.73% |
| Average Diluted Shares Outstanding | 27.73% | 30.69% | 26.67% | 25.78% | 25.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |